

**CURRICULUM VITAE****PERSONAL STATUS**

Name: Ludwig Achim Kappos  
 Year, Place of birth: 1953, Erlangen, Germany  
 Nationalities: Swiss(Riehen,BS), Greek  
 Marital status: married, three daughters  
 Business adress: Chair Department of Neurology, University Hospital  
 Petersgraben 4, CH-4031 Basel, Switzerland  
 Tel: +41 (0) 61 265-4464, -2525 (main)  
 Fax: +41 (0) 61 265-4198  
 Email: ludwig.kappos@usb.ch  
 OrcID: 0000-0003-4175-5509

**EDUCATION**

1958-1970 Primary, Secondary and High School in Athens (Greece)  
 1970-1977 Medical studies, University of Würzburg (Germany)  
 1973-1980 Diploma in Psychology, University of Würzburg  
 1976-1980 Training in Behavioral Therapy and Group Psychotherapy

**ACADEMIC CAREER**

1980 Medical Doctor, University of Würzburg  
 1988 Venia legendi, Neurology, University of Würzburg  
 1988 Assistant Professor, State of Bavaria  
 1994 Professor of Neurology, Clinical Neuroimmunology, Medical Faculty, University of Basel  
 2008 Chair, Neurology, Medical Faculty, University of Basel

**PROFESSIONAL CAREER**

1977 - 1985 Internships in Internal Medicine, Surgery and Psychiatry, Residency in Neurology  
 May 1982 - Sep 1985 Research Associate, Max-Planck-Society, Clinical Research Unit for MS, University of Würzburg  
 Sep 1983 - Feb 1990 Staff Attending Neurologist, Dept Neurology, University of Würzburg  
 Oct 1985 - Feb 1990 Deputy Chief, Division Clinical Neurology, Max-Planck-Society, Clinical Research Unit for MS, University of Würzburg  
 Mar 1990 – June 2007 Head Outpatient Clinic Neurology-Neurosurgery, Vice Chair, Neurology, University Hospital, Basel  
 July 2007 – Nov 2008 Acting Chair, Neurology, University Hospital, Basel  
 Since Dec 2008 Chair, Neurologic Clinic and Policlinic, University Hospital, Basel  
 Since June 2008- Academic Head Departments of Medicine and Neurology, Medical Faculty  
 Member Executive Boards: Departments of Medicine, Clinical Research, Biomedical Engineering

**ACKNOWLEDGEMENTS**

Prize of the "Kuratorium der Unterfränkischen Gedenkjahrstiftung für Wissenschaft" 1982; Käte-Hammersen Prize (with the Clinical Research Unit for MS) 1988; Prize of the "Langheinrich Stiftung", Berlin for Research in the field of MS 1989; Aventis MS-Research Prize of the Swiss MS-Society 2001; European Charcot Foundation Lecture 2005; ECTRIMS Lecture 2011; ECTRIMS Honorary Member 2013; Honorary Doctor Awards (Dr.med.h.c.): Medical Science Faculty, Aristotle University, Thessaloniki, Greece 2014; Faculty of Medicine, University of Thessaly, Larissa, Greece 2015; Faculty of Medicine, University of Patras, Greece 2016; Honorary Member of the French Society of Neurology, Paris 2016; Fellow of the American Academy of Neurology (FAAN) 2017, Research Prize of the Roman, Marga and Mareille Sobek Foundation 2017, Honorary President Scientific Advisory Board of the Swiss MS Society 2018

**MEMBERSHIPS**

Executive Board ENS (Treasurer, until 2014); Executive Committee ECTRIMS (Secretary, until 12/2010), Board European Charcot Foundation; Editorial Boards: "Journal of Neurology", "Multiple Sclerosis Journal", "Neurology and Clinical Neuroscience", "Multiple Sclerosis and Related Disorders", "Neurological Research and Practice" and others.

**PUBLICATIONS**

>750 original papers, chapters and reviews in scientific journals and books, >950 published abstracts, >600 invited lectures and seminars

**SCIENTIFIC PROJECTS**

- Neurobiology** (1990-...) Molecular analysis of protein kinase expression in myelination and remyelination (with G. Miescher); Neurofilaments as Biomarkers of disease severity and therapeutic effects in MS and other neurological diseases (with J. Kuhle).
- Neuroimmunology** (1984-...) Clinical neuroimmunological findings, mainly phenotypical characterization of lymphocyte subpopulations, short term cultures in relation to the course of multiple sclerosis and myasthenia gravis; MBP specific T cell lines in MS and controls; role of gamma-delta-cells; matrix-metalloproteases in inflammatory nervous system diseases; glycolipids as new antigens for T-cells; effects of immunomodulatory drugs on phenotype and function of immune cells (IFN-beta, glatiramer acetate, natalizumab, fingolimod, Dimethylfumarate); prognostic role of antimyelin antibodies in early MS.
- Transcriptomics** (2000-...) Gene expression in MS-lesions; NAWM, blood and CSF; transcriptomics in the characterization of MS-subtypes, defining disease phases, prognosis and treatment response, Micro RNA in MS.
- Neurogenetics** (2004-...) GeneMSA and SUMMIT project (lead investigator): Geno-phenotypic associations in MS, including full scale genetic analysis, transcriptomics and imaging in 1'000 MS patients and 1'000 controls with 2-12 years of follow-up.
- Standardised assessment of neurological impairment & disability** (1985-...) Quantification and standardisation of clinical measures for the use in therapeutic studies, training of investigators in most international therapeutic studies in MS, including development of audiovisual, www-based and hand-held documentation, teaching and certification tools ("Neurostatus"); Assess MS.
- Neuroimaging** (1985-...) MRI in the assessment of treatment response in MS; quantification, clinical-immunological correlation; role of paramagnetic contrast agents; MS MRI Evaluation Centre and Medical Image Analysis Centre (MIAC) (with E.W. Radue) (quantification of MRI outcomes for international studies); Research Group Tissue Characterisation (with A. Gass, T. Sprenger: (initiation and funding for research professorships, development of more tissue and function specific measures in demyelinating and degenerative diseases (MS, dementia); assessment of brainstem, cerebellum and spinal cord, cortical and deep gray matter atrophy.
- Design & conduct of international multicenter studies** (1982 - ...) PI Multicenter study cyclosporin A vs. azathioprine in MS; cyclosporin A vs. azathioprine in myasthenia gravis; Comparison of oral and intrathecal steroids in MS Pilot studies on mitoxantrone in MS; PI of the European multicenter study 15 $\pm$ deoxyspergualin vs. placebo in MS; SC rIFN $\beta$ -1a vs. placebo in relapsing MS (PRISMS), PI long term follow up study; Steering committee of European multicenter study on recombinant interferon beta-1b in SP MS; Dose comparison study rIFN $\beta$ -1a in relapsing MS (liaison and publication committee); International phase II-study altered peptide ligands (APL) in RR MS (planning and chair steering committee); European phase II-study for oral IFN beta-1a in RR MS (steering committee); European comparative trial autologous stem cell transplantation vs. mitoxantrone in MS (steering group); International study oral copaxone for RR MS (European coordinator); Phase III study natalizumab vs. placebo (steering committee); Teriflunomide Global Phase III Program in MS (steering committee); BEST-PGx (sponsor, lead investigator); BEST (lead investigator); BENEFIT-study (lead investigator, steering committee); BEYOND study (steering committee); REFLEX and REFLEXION studies (steering committee); International lead investigator of: phase II CCI-779 (temsirolimus); Allegro (Phase III study) Laquinimod in RRMS (steering committee); PI Phase II FTY720; FTY720 phase III programme in RR MS (chair of steering committee); PI Phase II DMF in RR MS; DEFINE (DMF phase III) in RR MS (steering committee); DECIDE (Dac Hyp in RR MS, Phase III; Chair Steering committee); Ocrelizumab phase II in RR MS (international lead investigator); Ocrelizumab phase III in MS Program (international SC, PI Opera II); Siponimod in RR MS (Phase II, steering committee); Siponimod in SP MS (Phase III, chair SC); Amiselimod in RRMS (Phase II, chair SC); Ponesimod vs Teriflunomide in relapsing MS (Phase III, chair SC); Ponesimod added to DMF vs DMF in relapsing MS (Phase III, Chair SC); Ofatumumab vs Teriflunomide in relapsing MS (Phase III, Co-Lead Investigator).

**Multicenter  
Observational Studies  
(1998 - ...**

Longterm Follow up of PRISMS (8y, 15y), EU-SPMS 10y; BENEFIT (5y, 8y, 11y, 15y), Longterms (fingolimod). SUMMIT Prospective Cohort Study, supported by NMSS (with UCSF, Harvard, VUMC Amsterdam); Swiss MS Cohort Study (National Observational Study including all Swiss University Hospitals and 3 Cantonal Hospitals; Sampling of Standardized Clinical and Imaging Data and Biological Fluids).

**Neuropsychology  
(1985-...)**

Evaluation of computer assisted training of attentional deficits (pilot study in Basel, multicenter study with Swiss Rehabilitation Clinics. Functional MRI paradigms for the study of attentional and memory deficits and the effect of training; MS fatigue: assessment and pathophysiology

Basel, May 5, 2019

L. Kappos